Corneal ulcer
diseaseOn this page
Also known as cornea ulcer diseaseulcer disease of corneaUlcer, corneal
Summary
Corneal ulcer (MONDO:0004577) is a disease (an umbrella term covering 6 Mondo subtypes) with 9 GWAS associations across 6 studies and 44 clinical trials. Top therapeutic interventions include riboflavin, voriconazole, and natamycin. A subtype of keratitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 6 Mondo subtypes
- GWAS associations: 9
- Clinical trials: 44
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | corneal ulcer |
| Mondo ID | MONDO:0004577 |
| MeSH | D003320 |
| DOID | DOID:8463 |
| ICD-10-CM | H16.0 |
| ICD-11 | 2089700977 |
| NCIT | C50515 |
| SNOMED CT | 91514001 |
| UMLS | C0010043 |
| MedGen | 40486 |
| Anatomy (UBERON) | UBERON:0000964 |
| Is cancer (heuristic) | no |
Also known as: cornea ulcer disease · ulcer disease of cornea · Ulcer, corneal
Data availability: 9 GWAS associations (6 studies) · 1 HPO phenotype.
Disease family
This is a subtype of keratitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › corneal disorder › keratitis › corneal ulcer
Related subtypes (10): macular keratitis, superficial keratitis, photokeratitis, scleroperikeratitis, filamentary keratitis, keratoconjunctivitis, deep keratitis, corneal neovascularization, autosomal dominant keratitis, corneal infection
Subtypes (6): Mooren ulcer, mycotic corneal ulcer, marginal corneal ulcer, ring corneal ulcer, perforated corneal ulcer, central corneal ulcer
Genetics & variants
GWAS landscape
9 GWAS associations across 6 studies. Top hits map to 7 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs754763810 | 1e-13 | RBMXP1 - PRR11P1 | C | 3.21 |
| rs549104783 | 6e-13 | UBE2V2 - IDI1P2 | C | 2.98 |
| rs77821854 | 2e-12 | SLC9A9 | A | 1.96 |
| rs544491865 | 1e-11 | CCBE1 | T | 4.51 |
| rs556569191 | 2e-11 | ALPK1 | T | 2.43 |
| rs183215388 | 3e-11 | NTF4 | C | 2.7 |
| rs112079433 | 4e-11 | UTRN | G | 1.38 |
| rs142445743 | 4e-11 | LINC02715, RDX | T | 2.99 |
| rs117428723 | 2e-08 | NIHCOLE - RNU6-334P | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90477722 | Verma A | 2024 | 1,488 | 448,953 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480083 | Verma A | 2024 | 399 | 121,285 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481925 | Verma A | 2024 | 399 | 121,285 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651567 | Liu TY | 2025 | 322 | 217,632 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90481924 | Verma A | 2024 | 204 | 59,557 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436004 | Zhou W | 2018 | 141 | 399,306 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 1 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 8 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 8 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 6 |
| intergenic_variant | 2 |
| 5_prime_UTR_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs754763810 | 6 | 48947305 | C>A | 0 | intergenic_variant | RBMXP1 - PRR11P1 | 1e-13 | Tier 4: intronic/intergenic |
| rs549104783 | 8 | 48106294 | C>G | 0.001 | intergenic_variant | UBE2V2 - IDI1P2 | 6e-13 | Tier 4: intronic/intergenic |
| rs77821854 | 3 | 143424794 | A>G | 0.002 | intron_variant | SLC9A9 | 2e-12 | Tier 4: intronic/intergenic |
| rs544491865 | 18 | 59666144 | T>C | 0.001 | intron_variant | CCBE1 | 1e-11 | Tier 4: intronic/intergenic |
| rs556569191 | 4 | 112325350 | T>C | 0.001 | intron_variant | ALPK1 | 2e-11 | Tier 4: intronic/intergenic |
| rs183215388 | 19 | 49064793 | C>G | 0.001 | 5_prime_UTR_variant | NTF4 | 3e-11 | Tier 2: splice/UTR |
| rs112079433 | 6 | 144367255 | G>C,T | 0.002 | intron_variant | UTRN | 4e-11 | Tier 4: intronic/intergenic |
| rs142445743 | 11 | 109957462 | T>A,C | 0.001 | intron_variant | LINC02715, RDX | 4e-11 | Tier 4: intronic/intergenic |
| rs117428723 | 5 | 104542952 | A>C | intron_variant | NIHCOLE - RNU6-334P | 2e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ciprofloxacin, Gatifloxacin, Moxifloxacin.
Clinical trials & evidence
Clinical trials
Clinical trials: 44.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 23 |
| PHASE3 | 6 |
| PHASE2 | 5 |
| PHASE1 | 3 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00324168 | PHASE4 | COMPLETED | Steroids for Corneal Ulcers Trial |
| NCT06411145 | PHASE4 | WITHDRAWN | Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis |
| NCT06658002 | PHASE3 | RECRUITING | Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A |
| NCT00996736 | PHASE3 | COMPLETED | Mycotic Ulcer Treatment Trial I |
| NCT00997035 | PHASE3 | COMPLETED | The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo |
| NCT01794312 | PHASE3 | COMPLETED | Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer |
| NCT02570321 | PHASE3 | COMPLETED | Cross-linking for Corneal Ulcers Treatment Trial |
| NCT02731638 | PHASE3 | COMPLETED | Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers |
| NCT05255016 | PHASE2/PHASE3 | UNKNOWN | Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers |
| NCT05255107 | PHASE2/PHASE3 | UNKNOWN | Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers |
| NCT05705024 | PHASE2 | RECRUITING | Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells |
| NCT07308938 | PHASE2 | NOT_YET_RECRUITING | Fluorometholone Study |
| NCT00386958 | PHASE2 | COMPLETED | A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers |
| NCT01756456 | PHASE1/PHASE2 | COMPLETED | Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. |
| NCT01928693 | PHASE2 | TERMINATED | A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. |
| NCT04484402 | PHASE1/PHASE2 | COMPLETED | Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells |
| NCT05172349 | PHASE2 | WITHDRAWN | Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers |
| NCT00155402 | PHASE1 | WITHDRAWN | The Application of Fibrin Glue in Ocular Surface Diseases |
| NCT02068430 | PHASE1 | COMPLETED | Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection |
| NCT05200000 | PHASE1 | COMPLETED | Wharton’s Jelly Eye Drops in the Treatment of Chronic Keratitis |
| NCT02168790 | EARLY_PHASE1 | COMPLETED | Safety Study of a Sutureless Amniotic Membran Transplantation to Treat Ocular Surface Disorders (Expanded Access) |
| NCT01969786 | Not specified | ACTIVE_NOT_RECRUITING | Village Integrated Eye Workers Trial |
| NCT07377513 | Not specified | RECRUITING | Follow-up Compliance for Corneal Ulcer Patients With SMS Reminder |
| NCT07394257 | Not specified | RECRUITING | Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis |
| NCT00789646 | Not specified | TERMINATED | Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients |
| NCT01104961 | Not specified | WITHDRAWN | Studying the Relationship Between Contact Lens Packaging Solutions and Bacterial Binding to Surface Eye Cells |
| NCT01242839 | Not specified | COMPLETED | Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing |
| NCT01244776 | Not specified | UNKNOWN | Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer |
| NCT01560208 | Not specified | UNKNOWN | The Asia Cornea Society Infectious Keratitis Study |
| NCT02138019 | Not specified | COMPLETED | The Application of Fibrin Glue (Tissucol Duo Quick) in External Eye Surgeries |
| NCT02277054 | Not specified | COMPLETED | Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty |
| NCT02284698 | Not specified | UNKNOWN | Corneal Ulcer Prevention Through Health Education |
| NCT02293876 | Not specified | COMPLETED | Corneal Lesions in Intensive Care Unit (ICU) Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center |
| NCT02826174 | Not specified | UNKNOWN | Topical Anesthesia for Closed PKP vs Retrobulbar Anesthesia for Open-sky PKP |
| NCT02984904 | Not specified | COMPLETED | Fusarium Keratitits in Spain 2012 to 2014 |
| NCT04054817 | Not specified | COMPLETED | ACRO Biocornea Clinical Trial in Taiwan |
| NCT04075669 | Not specified | UNKNOWN | Multiplex Strip Polymerase Chain Reaction for Diagnosis of Eye Infection Diseases From Corneal Scraping Samples |
| NCT04164407 | Not specified | UNKNOWN | Keratoconus, Corneal Diseases and Transplant Registry |
| NCT04230811 | Not specified | WITHDRAWN | Diagnosing Corneal Infection |
| NCT04820010 | Not specified | COMPLETED | Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RIBOFLAVIN | 4 | 3 |
| VORICONAZOLE | 4 | 3 |
| NATAMYCIN | 4 | 2 |
| ACYCLOVIR | 4 | 1 |
| BESIFLOXACIN HYDROCHLORIDE | 4 | 1 |
| CENEGERMIN | 4 | 1 |
| FLUOROMETHOLONE | 4 | 1 |
| GATIFLOXACIN | 4 | 1 |
| HYALURONATE SODIUM | 4 | 1 |
| MOXIFLOXACIN HYDROCHLORIDE | 4 | 1 |
| POVIDONE-IODINE | 4 | 1 |
| TOBRAMYCIN | 4 | 1 |
| FIBRIN | 3 | 1 |
| CHEMBL511565 | 0 | 3 |
| CHEMBL5267279 | 0 | 3 |
| CHEMBL4740747 | 0 | 2 |
| CHEMBL1716015 | 0 | 1 |